Employees: NN (None)Legal category: 5485Size: PMECreation date: 2009-03-04 (17 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: MAMOUDZOU (97600), Mayotte
SELARL PHARMACIE MIALLET : revenue, balance sheet and financial ratios
SELARL PHARMACIE MIALLET is a French company
founded 17 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in MAMOUDZOU (97600),
this company of category PME
shows in 2023 a revenue of 1.5 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE MIALLET (SIREN 510883267)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
1 491 735 €
N/C
N/C
N/C
N/C
N/C
2 114 184 €
Net income
13 332 €
105 372 €
68 905 €
123 433 €
274 376 €
256 937 €
281 510 €
216 354 €
210 106 €
EBITDA
N/C
N/C
112 898 €
N/C
N/C
N/C
N/C
N/C
376 528 €
Net margin
N/C
N/C
4.6%
N/C
N/C
N/C
N/C
N/C
9.9%
Revenue and income statement
In 2025, SELARL PHARMACIE MIALLET generates positive net income of 13 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 210 k€ -> 13 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
13 332 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 36%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 61%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
35.625%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
60.951%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
82.134
56.317
32.271
31.459
26.116
14.955
59.312
45.56
35.625
Financial autonomy
42.416
47.471
57.364
59.352
66.454
73.075
54.258
59.57
60.951
Repayment capacity
2.203
None
None
None
None
None
4.699
None
None
Cash flow / Revenue
10.774%
None%
None%
None%
None%
None%
7.471%
None%
None%
Sector positioning
Debt ratio
35.622025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Good-6 pts over 3 years
In 2025, the debt ratio of SELARL PHARMACIE MIALLET (35.62) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
60.95%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Good
In 2025, the financial autonomy of SELARL PHARMACIE MIALLET (61.0%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
4.7 years2023
2023
Q1: 0.95 years
Med: 3.59 years
Q3: 7.48 years
Average
In 2023, the repayment capacity of SELARL PHARMACIE MIALLET (4.70) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 131.68. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
79.047
91.016
89.808
67.418
96.256
119.853
150.909
153.241
131.679
Interest coverage
8.983
None
None
None
None
None
4.523
None
None
Sector positioning
Liquidity ratio
131.682025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Average-7 pts over 3 years
In 2025, the liquidity ratio of SELARL PHARMACIE MIALLET (131.68) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
4.52x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Good
In 2023, the interest coverage of SELARL PHARMACIE MIALLET (4.5x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELARL PHARMACIE MIALLET
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
79 092 €
0 €
0 €
0 €
0 €
0 €
195 671 €
0 €
0 €
Inventory turnover (days)
28
0
0
0
0
0
41
0
0
Customer payment term (days)
6
0
0
0
0
0
12
0
0
Supplier payment term (days)
47
0
0
0
0
0
49
0
0
Positioning of SELARL PHARMACIE MIALLET in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELARL PHARMACIE MIALLET is estimated at
211 780 €
(range 143 715€ - 332 312€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
143k€211k€332k€
211 780 €Range: 143 715€ - 332 312€
NAF 5 année 2025
Valuation method used
Net Income Multiple
13 332 €
×
15.9x
=211 780 €
Range: 143 715€ - 332 313€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE MIALLET with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE MIALLET
What is the revenue of SELARL PHARMACIE MIALLET ?
The revenue of SELARL PHARMACIE MIALLET in 2023 is 1.5 M€.
Is SELARL PHARMACIE MIALLET profitable?
Yes, SELARL PHARMACIE MIALLET generated a net profit of 13 k€ in 2025.
Where is the headquarters of SELARL PHARMACIE MIALLET ?
The headquarters of SELARL PHARMACIE MIALLET is located in MAMOUDZOU (97600), in the department Mayotte.
Where to find the tax return of SELARL PHARMACIE MIALLET ?
The tax return of SELARL PHARMACIE MIALLET is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE MIALLET operate?
SELARL PHARMACIE MIALLET operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart